WCLC 2023 – Yasushi Goto
Yasushi Goto discusses the effects of delta-like ligand 3 (DLL3) expression status on clinical outcomes in treated patients with small-cell lung cancer, explains in which ways DLL3 can be used as a direct target for treatment and highlights the challenges and future perspectives regarding DLL3-directed therapies in patients with SCLC. Lastly, he shares his thoughts on the optimal first-line therapy for patients with pleural mesothelioma.
Here is the full WCLC 2023 report.
More posts
MARS 2: no benefit of decortication in early-stage malignant mesothelioma
MARS 2: no benefit of decortication in early-stage malignant mesothelioma Surgery in th
Trop-2–directed ADCs in conjunction with immunotherapy: EVOKE-02 and TROPION-Lung04
Trop-2–directed ADCs in conjunction with immunotherapy: EVOKE-02 and TROPION-Lung04
Refining first-line regimens for extensive-stage small-cell lung cancer
Refining first-line regimens for extensive-stage small-cell lung cancer Benmels
Improved anti-EGFR strategies and other targeted innovations
Improved anti-EGFR strategies and other targeted innovations FLAURA2: first-lin
Detection and treatment of early-stage lung cancer: recent insights
Detection and treatment of early-stage lung cancer: recent insights The signifi
Preface – WCLC 2023
Preface – WCLC 2023 © private – Navneet Singh, MD DM FRCP FASCO, Professor of Pulmona
